StockMirror — Stock Screener

SYNGENE Q3 FY26 Results & Earnings Analysis

Sentiment: Bad (Confidence: high)

Earnings Summary

Syngene's Q3 FY26 results were severely impacted by a continued, significant volume decline from a single large-molecule product (Librela for Zoetis), leading to a 3% YoY revenue drop, a 44% decline in PAT before exceptionals, and a sharp cut in FY26 guidance from growth to a 3-5% decline. Underlying business ex-this product is growing at a high-single/low-double digit rate. Management expects the headwind to persist for multiple quarters and is focused on accelerating growth in the rest of the business and diversifying the client/product base to mitigate such concentration risk in the future.

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

The strategy involves investing in capabilities and capacity for growth (CapEx, talent) while aiming for operational efficiency. The current margin pressure is an outcome of an external volume shock, not a strategic shift. The long-term goal is to build a diversified, profitable business.

About SYNGENE INTERNATIONAL LIMITED

SYNGENE INTERNATIONAL LIMITED (SYNGENE) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More